ADORA3 and psoriasis: This scoping review summarizes the available data on efficacy and safety of novel oral and topical therapies for psoriasis, either in clinical development or under investigation; they include Jak inhibitors, oral inhibitors of TNF, IL-17, and IL-23, retinoic acid-related orphan receptors (ROR)γT inhibitors, sphingosine-1-phosphate receptor 1 (S1PR) inhibitors, A3 adenosine receptor (A3AR) agonists, heat shock protein (HSP)90 inhibitors, Rho-associated protein kinase (ROCK)2 inhibitors, and phosphodiesterase (PDE) 4 inhibiros, among others (Figure 1).